Genmab AS (GMAB)vsModerna Inc (MRNA)
GMAB
Genmab AS
$32.47
+0.74%
HEALTHCARE · Cap: $20.65B
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Genmab AS generates 85% more annual revenue ($4.13B vs $2.23B). GMAB leads profitability with a 19.1% profit margin vs -141.4%. GMAB earns a higher WallStSmart Score of 53/100 (C-).
GMAB
Buy53
out of 100
Grade: C-
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+48.6%
Fair Value
$58.54
Current Price
$32.47
$26.07 discount
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.2%
Revenue surging 24.9% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Weak financial health signals
Expensive relative to growth rate
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GMAB
The strongest argument for GMAB centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 19.1% and operating margin at 35.2%. Revenue growth of 24.9% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : GMAB
The primary concerns for GMAB are P/E Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
GMAB profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
GMAB is growing revenue faster at 24.9% — sustainability is the question.
GMAB generates stronger free cash flow (48M), providing more financial flexibility.
Bottom Line
GMAB scores higher overall (53/100 vs 21/100), backed by strong 19.1% margins and 24.9% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?